期刊文献+

恶性黑素瘤患者T细胞化学趋化功能 被引量:2

T Cell Chemotactic Response in Patients with Primary and Metastatic Malignant Melanoma
原文传递
导出
摘要 目的 探讨恶性黑素瘤患者循环T细胞在体外对单核细胞化学趋化蛋白 1 (MCP 1 )的化学趋化功能及其与肿瘤浸润淋巴细胞 (TIL)及与肿瘤转移之间的关系。方法 用微量化学趋化装置和免疫组化方法测定患者T细胞对MCP 1的化学趋化功能和TIL计数。结果 原发性和转移性黑素瘤患者T细胞对MCP 1的化学趋化功能均明显低下 ,而基底细胞癌患者T细胞的化学趋化功能正常。免疫组化研究发现原发性恶性黑素瘤TIL数量与T细胞的化学趋化功能之间无关。结论 原发性和转移性恶性黑素瘤患者循环T细胞特异性地对MCP 1的化学趋化反应低下。这可能是由于这些细胞上的MCP Objective To address the question whether circulating T cells from the patients with primary and metastatic malignant melanoma show altered chemotaxis to monocyte chemotactic protein 1 (MCP 1) and its relation to tumor infiltrating lymphocyte (TIL) and metastasis. Methods Chemotactic responsiveness of T cells towards MCP 1 and immuno histochemistry study were investigated in patients with primary and metastatic melanoma compared to patients with basal cell carcinoma and healthy persons. Results T cells from primary and metastatic melanoma patients showed a significantly decreased chemotactic migration towards MCP 1 and that T cells from patients with basal cell carcinoma showed normal chemotactic response. Immuno histochemistry study showed that there was no correlation between the density of TIL and the decreased chemotaxis of circulating T cells to MCP 1 in patients with primary melanoma. Conclusion Circulating T cells from patients with primary and metastatic malignant melanoma show a MCP 1 specific decrease in chemotactic migration, this may be due to abnormal expression or modulation of MCP 1 receptor on these cells.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 1998年第4期209-211,共3页 Chinese Journal of Dermatology
基金 浙江省卫生厅科研基金资助
关键词 黑色素瘤 T淋巴细胞 趋化性 Melanoma T Lymphocytes Chemotaxis
  • 相关文献

参考文献2

  • 1郑敏,Exp Dermatol,1996年,5期,334页
  • 2郑敏,Clin Biotechnol,1991年,3期,197页

同被引文献18

  • 1赖日权,郝春志.肝细胞癌动脉栓塞化疗后的病理观察[J].中华病理学杂志,1993,22(1):19-21. 被引量:2
  • 2周云龙.恶性黑素瘤的诱发因素及早期诊断[J].临床皮肤科杂志,1994,23(2):100-101. 被引量:4
  • 3侯建新,李素英,刘文君,李盛梅,杨海英.Giemsa染色在黑色素细胞病变免疫组化复染中应用[J].临床与实验病理学杂志,1996,12(2):178-178. 被引量:7
  • 4陈天水.无色素性黑色素瘤病理诊断释疑[J].临床与实验病理学杂志,1996,12(1):78-78. 被引量:6
  • 5Gabrilovich DI,Ciemik IF,Carbone DP.Dendritic cells in antitumor immune responses.I.Defective antigen presentation in tumor-bearing hosts.Cell Immunol,1996,170:101-110.
  • 6Enk AH,Jonuleit H,Saloga J,et al.Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma.Int J Cancer,1997,73:309-316.
  • 7Hochrein H,O'Keeffe M,Luff T,et al.Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells.J Exp Med,2000,192:823-833.
  • 8Duda DG,Sunamura M,Lozonschi L,et al.Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12.Cancer Res,2000,60:1111-1116.
  • 9Kiertscher SM,Luo J,Dubinett SM,et al.Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells.J Immunol,2000,164:1269-1276.
  • 10Avila-Moreno F,Lopez-Gonzalez JS,Galindo-Rodriguez G,et al.Lung squamous cell carcinoma and adenocarcinoma cell lines use different mediators to induce comparable phenotypic and functional changes in human monocyte-derived dendritic cells.Cancer Immunol Immunother,2006,55:598-611.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部